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Summary
Using recombinant DNA technology, we have generated Chinese hamster ovary (CHO) cell
lines that synthesize latent transforming growth factor Nt (TGF-/3t) to study immune regulation
by TGF-Rt. In vitro, latent TGF-(3t synthesized by transfectants or added exogenously as a
purified complex after activation inhibited CTL generation to a similar extent as seen with
acid-activated recombinant human (rHu) TGF-tit. In vivo, serum from nulnu mice bearing
CHO/TGF-R1 tumors contained significant levels of latent TGF-al in addition to depressed
natural killer (NK) activity in spleens which paralleled that seen in C3H/HeJ mice treated with
acid-activated rHuTGF-tit . rHuTGF-#l treatment of mice receiving heart allografts resulted in
significant enhancement of organ graft survival. Because of possible regulated tissue-specific
activation, administration oflatent rather than active TGF-0 may provide a better route to deliver
this powerful immunosuppressive agent in vivo.
T
ransforming growth factors encompass a family ofpoly-
peptides that regulate the growth and differentiation of
both normal and transformed cells (1, 2). One of these,
TGF-a1, has been isolated and purified from various normal
and neoplastic cells. Molecular cloning and sequencingofthe
cDNA for TGF-/mot (3) in conjunction with protein struc-
tural data (4-6) showed that TGF-f+1 is synthesized as a
precursor protein of 391 amino acid residues and subsequently
processed after signal peptidase and proteolytic cleavage to
a 112 residue (Mr 12,500) form. The active or "mature"
TGF-#t homodimer (25 kD) is noncovalently associated
with the remainder of its precursor form (75-kD dimer), and
in platelets covalently linked with one molecule of TGF-R1
binding protein (135 kD) (5, 7, 8) or in serum associated
with a2-macroglobulin (9) to form a high molecular weight
inactive "latent" complex unable to bind TGF-0 cellular
receptors (10). TGF-,81 can be activated by exposure to ex-
tremes ofpH, heat, or by treatment with chaotropic agents,
proteases, ;or glycosidases (11-14). However, the physiolog-
ical processes by which latent TGF-01 is activated have not
yet been fully elucidated.
Numerous studies have described the pleiotropic nature
of the biologically active form of TGF-a1. In addition to its
potent effects on cell proliferation and differentiation, TGF-/31
plays an active role in wound healing, tissue repair, and regu-
lation ofimmune responses (1, 15, 16). The immunoregulatory
properties of TGF-01 include inhibition of thymocyte pro-
liferation (17-19), T and B cell proliferation, production of
IgM or IgG (20-22), but not IgA synthesis which TGF-a
enhances (23, 24), cytokine production (25), NK cell activity
(26), cytotoxic T cell development (27-29), and lymphokine-
activated killer (LAK)1 cell activity (28, 30). With regard
to monocytes/macrophages, TGF-0 displays both inhibitory
and stimulatory effects. TGF-0 can induce monocyte che-
motaxis, and enhance mRNA expression for TNF-ci and IL1
(31, 32) while deactivating macrophages by reducing their
capacity to release H202, cytotoxicity activity, class II and
Fc,R2 expression, as well as TNF-ci and 11,1 production,
thus perhaps imposing negative feedback and limiting the
detrimental effects of toxic monokines (33-36) .
Many of the studies that establish TGF-0 as a regulator
of immune function have examined the immunoregulatory
effects ofacid-activated TGF-0 in vitro. However, the poten-
tial clinical usefulness of TGF-0 as an immunosuppressant
relies also on in vivo studies, few ofwhich have been reported.
Second, physiological TGF-# is first presented in vivo as a
' Abbreviations used in this paper. CHO, Chinese hamster ovary cells; B6,
C57BL/6; dhfr, dihydrofolate reductase; Hu, human; LAK, lymphocyte
activated killer cell; LAP, latency-associated peptide.
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andregulating immune functions. It is not clearfrom previous
studies using activated TGF-0 that latent or endogenous
TGF-0 can be activated both in vitro andin vivo to regulate
immune responses. To addressthesequestions, we investigate
the immunoregulatory properties of TGF-0 using latent
recombinant human TGF-{$1 (rHuTGF-Oi) produced in Chi-
nese hamster ovary (CHO) cells and compare the immune
activities of latent and acid-activated rHuTGF-at. We con-
clude that mechanisms exist in vitro and in vivo to activate
latent TGF-0 which in an autocrine or paracrine manner can
suppress immune function. Thepossible role ofactive TGF-0
in immune surveillance is discussed.
Materials and Methods
Cell Culture and cDNA Transfection.
￿
Chinese hamster ovary
(CHO) cellsdeficientin dihydrofolatereductase(dhfr) activity (37)
were grown in DME/F12 (50:50) medium (Gibco Laboratories,
GrandIsland, NY)supplemented with 1 g/liter glucose, 10% FCS
(HyClone,Logan, UT), 2MM L-glutamine, penicillin (100 U/ml),
andstreptomycin (100 Wg/ml) (Gibco)and0.133 mM glycine, 0.11
mM hypoxanthine, 0.02 mM thymidine (GHT). CHO dhfr- cells
(2 x 106) were cotransfected with 1 wg of the expression vector
p(SBO) containing the TGF-S, cDNA (3) driven from the cyto-
megalovirus immediateearlypromoter in pRK5 (kindly provided
by R. Klein and D.V. Goeddel, Genentech, Inc.) and 100 ng of
pFD11 which encodes the dhfr gene. Cells stably expressing the
dhfr gene were selected in DME/F12 lacking GHT and 10% dia-
lyzedFCS. Individual transfectant clones were selected, expanded
in culture, and screened for TGF-S, production by either RIA (6)
or bioassay (described below). Confirmation of rHuTGF-a, pro-
duction was also determined by SDS-PAGE (6). The integrated
plasmidcopy number was amplified by culturing cells in the pres-
ence ofup to 1-2F.M methotrexate in selectivemedium. For some
experiments we used active rHdIGF-a,produced by CHO trans-
fectant cells, purified to 0.8 mg/ml (1 pg endotoxin/lAg protein)
and acid-activated by dialysis against 20 mM sodium acetate, pH
4.0. Latent rHuTGF-S, in CHO transfectant-conditioned medium
was purified by sequential cation exchange andhydrophobic chro-
matography (12). The latency of purified rHuTGF-I8, was con-
firmed both before and after its isolation by inactivity in bioassay
or TGF-0 receptor binding studies. The structure of purified la-
tent rHuTGF-S, is representative of the small latent TGF-0 com-
plex composed of the active 25-kD TGF-IQ dieter noncovalently
associated with the 75-kD precursor remnant, but lacking the
135-kD bindingprotein foundin the platelet largelatent complex
(6). For ease in reading the text the following abbreviations are
used; CHO for parental CHOdhfr- cells, CHOdhfr' and CHO/
TGF-0, referto CHO dhfr- mutant cell line that has been trans-
fected and expresses dhfr, dhfr and rHuTGF-I#, activities, respec-
tively.
TG-/3 Bioassay. A subclone of the Mv1Lumink lung cell line
(American Type Culture Collection, Rockville, MD) isolated in
our laboratory was used to measure TGF-0 activity (38). Condi-
tionedmedium or serumwere assayedeitheruntreatedor aftertreat-
ment with 0.12 N HCl for 15 min at room temperature followed
by neutralization with O.1M HEPES buffer containing 0.144 M
NaOH (acid-activated). Samples diluted in MEM supplemented
with 2 MM L-glutamine, 1 mM sodium pyruvate, 0.1 mM nones-
sential amino acids, 100 U/ml penicillin, 100ttg/ml streptomycin
(completeMEM[CMEM]) (all reagents from Gibco Laboratories)
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and 0.1% FCS (HyClone) were added to cultures in 96-well flat-
bottomed microtiter plates (Costar, Cambridge, MA). The plates
were incubated at 37°C with 5% COa for 24 h and pulsed during
the last 4 h with 1 ttCi of ['H]thymidine in CMEM (6.7 Ci/
mmol; Amersham Corp., Arlington Heights, IL). Cellswere har-
vested usingaPHD Cell Harvester (Cambridge Technology, Inc.,
Watertown, MA) and ['H]TdRincorporation was measured with
aliquid scintillation counter.Results (picograms/milliliter ofTGF-S)
were calculated based on percent decrease in [3H]TdR incorpora-
tion compared with a rHuTGF-P, standard. The lower detection
limit of the bioassay was 10 pg/ml TGF-0. Samples containing
rHuTGF-S that show negligible bioactivity withoutacid-activation
are considered "latent," i.e., biologically inactive.
Animals.
￿
6-8-wk-old BALB/c nu/nu female mice andC57BL/6
(B6) female mice were purchased from Charles River Breeding
Laboratories, Wilmington, MA, C3H/HeJ female mice were ob-
tained fromJacksonLaboratories, BarHarbor, ME. For the trans-
plantation studies adult (8-10 wk) male C3H/km mice andneo-
natal (24-48 h) unsexed BALB/c mice were obtained from the
Department ofRadiobiology, Stanford University Medical Center,
Stanford, CA.
Animals Studies.
￿
BALB/c nu/nu mice were injected subcutane-
ously with 10' CHO or CHO/TGF-S transfected cells (>95%
viable as judged by Trypan blue exclusion) washed with PBS
(0.15 M NaCl, pH 7.0) and tumor size determined based on the
averageof the two cross-sectional diameters ofeach tumor. Serum
samples were withdrawn for quantitation of TGF-a, by bioassay
and spleens were assayed for NK activity. C3H/HeJmice were in-
jected by various routes with various doses of acid-activated
rHuTGF-/3, and spleen cells were assayed for NK activity.
For NK assays, spleen effector cells harvested from nu/nu or
C3H/HeJ mice were washed three times in CMEM and seeded
at various concentrations into 96-wellround-bottomed tissue cul-
ture plates (Costar) in CMEM supplemented with 10% FCS.YAC-1
target cells were labeled with 150 p.Ci of Na"Cr04 (5 mCi/ml;
Amersham Corp.) for 45 minat 37°C andafter threewashes with
CMEM, 104 target cellswere added to effector cells at various con-
centrations in 96-wellround-bottomed microtiter plates (Costar).
After 4 h of incubation at 37°C, culture supernatants were har-
vested (Skatron, Sterling, VA) and radioactivity was quantitated
using an automatic gammacounter(Micromedic Systems, Hersham,
PA). Percent specific lysis was calculated as 100 x [[cpm of com-
bined effector and target cells supernatants (experimental release)
- cpm of supernatants oftarget alone(spontaneous release)]/[cpm
afterlysis of targetswith 2% NP-40 (maximum release) - spon-
taneousrelease]). Results areexpressed as mean of triplicate deter-
minations ± SEM. Spontaneous release of target cells alone was
<10% of maximum for all experiments.
Cytotoxic T Lymphocyte Generation.
￿
CTLs were generated in
5-d cultures by incubation in T25 culture flasks of 2.5 x 10' B6
responding spleen cells and 2.5 x 106 stimulator CHO or CHO/
TGF-S, transfectant cells (irradiated 5,000 rad) in 10 m1 ofCMEM
+ 10% FCS. It should be noted that CHO/TGF-S, cells used in
the one-way MLC still accumulate TGF-0, into culture medium
after 5,000-rad irradiation. For some experiments B6-anti-CHO
CTLs were generated in thepresence of various concentrations of
acid-activated rHuTGF-0,, purified latent rHtfGF-0,, or acid-
activated purified latent rHuTGF-S,. After 5 d of culture effector
cells were assayed forcytolytic activity against various "Cr-labeled,
CHOcell lines that were labeled with "Cr as indicatedfor YAC-1
cells, and cytotoxicity assays were performed as described (27).
Mouse Heterotopic Cardiac Transplantation Model.
￿
Amousepinna
(ear)-heart transplant modelwasused in which anewbornBALB/c
Comparison of Active and Latent Transforming Growth Factor a,donor heartis transplanted into a surgicallyconstructed subdermal
pocket on the left dorsal pinna of an adult C3H/km recipient. Re-
cipient mice were anesthetized via intraperitonealinjection ofchloral
hydratedissolved in saline (25 mg/kg) and a2-mm epidermal/dermal
incision was made parallel to the body axis and 2-3 mm distal to
the ear-skulljunction. An oval subcutaneous pouch measuring 3-4
mm in diameter was formed on the ear by inserting one arm of
a small curved forceps into the incision separating the epi-
dermal/dermal layer from the underlying cartilage. The donor heart
was extracted en bloc via thoracotomy and both atria were removed.
Excess air and fluid were expressed from the pouch with a cotton
swab to facilitate maximal contact between donor and recipient
tissues.
Treatment groups received intraperitoneal injection ofeither ac-
tivated rHuTGF-#, at various doses or normal saline scheduled at
various intervals for 13 d after surgery. On the sixthpostoperative
day and on every other day thereafter until graftfailure, the grafts
were visually examined for contractions by using a stereomicro-
scope (Stereozoom No. 4; Bausch and Lomb Co., Rochester, NY)
at 10-2-fold magnification. Graft viability was evaluated in a bi-
nary fashion (+ or -) based upon the presence or absence ofgraft
contractions. All animals were weighed periodically to monitor drug
toxicity.
Results
Production ofLatent 7GRa1 by CHO Transfectants.
￿
Our
initial studies used CHO cells lines 12/20/6 and 61-
1/7C3C12A engineered to produce recombinant TGF-flt
(CHO/TGF-/31). To demonstrate that the TGF-01 secreted
from the CHO/TGF-01 transfectants was latent, condi-
tioned medium from CHO/TGF-Ot cells was analyzed for
bioactivity with or without acid-treatment. The data indi-
cate that clones 12/20/6 and 61-1/7C3C12A produced
significant quantities of recombinant latent TGF-fl, after 2 d
of in vitro culture ofwhich >90-98% was detectable by bio-
assay only after acid-activation (Table 1); the rHuTGF-Iat
secreted by the higher producing clone 12/20/6 was also in-
capable of binding TGF-0 cellular receptors as determined
by radioreceptor assay (Dr. Lalage Wakefield, personal com-
munication). Media obtained from parental CHO cells showed
background levels ofTGF-f. SDS-PAGE analysis showed that
the rHuTGF-01 synthesized by CHO transfectants formed
a high molecular weight complex with molecular species of
Mr 100,000 and 75,000, consistent with the presence of
processed precursor and precursor remnant, respectively, similar
in structure to platelet latent complex but lacking the 135-kD
binding protein (data not shown, reference 6).
rHuTGF-01 Inhibits CTL Generation In Vitm We have
shown previously that activated rHuTGF-fl, can inhibit the
generation of CTL in vitro but not their cytolytic activity
(27) . The studies presented now further examined whether
(a) latent TGF-,f3-secreting CHO cell lines can inhibit CTL
generation in vitro and (b) such CHO cells can serve as targets
for B6 anti-CHO-specific CTL. The data in Fig. 1 indicate
that 136 spleen cells generated potent CTL against the CHO
parental and CHO dhfr+ cells but not CHO/TGF-01
stimulator cells. In contrast, B6 anti CHO-specific CTL ex-
hibited similar cytolytic activity against the CHO parental
cells, CHO dhfr+ cells and CHO/TGF-/31 cells in 4-h CTL
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Table 1.
￿
rHuTGFA Synthesizer) by CHO Transfectant
Is Biologically Latent
" Test samples ofconditioned media (CM) were assayed either untreated
or acid-activated as described in Materials and Methods. Results were
obtained with 107 cells incubated for 48 h in CMEM and 10% FCS.
Data are from one representative experiment.
cytolytic assays (Fig. 1). These results indicate that transfec-
tion per se did not affect the ability of CHO cells to serve
as stimulators or targets for CTLs and that CHO cells that
secrete TGF-IQ are poor stimulators for CTL generation. Since
latent TGF-$ itself cannot bind cellular receptors, mechanisms
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Figure 1.
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Effect ofTGF-01 on in vitro CTL generation. B6-anti-CHO
(or CHO transfectant)-CTLs were generated in 5-d cultures as described
in Materials and Methods and tested in a 4-h s1Cr-release assay against
indicated target cells. Data presented are the mean of triplicate determina-
tions t SEM performed at an E/T ratio of 100:1. Similar results were
obtained at all E/T ratios tested (data not shown).
Untreated CM Acid-treated CM
CMEM <161
pg/ml
206 ± 6
CHO 230 ± 50 340 t 77
CHO/TGF-a1
clone 12/20/6 394 ± 18 17,783 ± 1,269
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Figure 2.
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Effect of latent TGF-0, on CTL generation. B6-anti-CHO
CTLs were generated in thepresence of 10 ng/mlacid-activated (E)),la-
tent (O) and acid-activated (A) rHuTGF-01, or non-TGF-01-containing
buffer ("), andwere tested in a4-hcytotoxicity assay against s1Cr-labeled
CHOtarget cellsas describedin Materials and Methods. Data shown are
themean oftriplicate values t SEMperformed at an E/Tratio of 25:1.
Similar results were obtained at allotherE/Tratios tested (datanotshown).
exist in vitro to convert latent TGF-0 into a biologically ac-
tive form that can regulate antitumor responses.
We next investigated whether latent/activatable rHuTGF-/31
was as effective in suppressing CTL generation in vitro as
acid-activated rHuTGF-01 . Both untreated and acid-activated
latent rHuTGF-101 inhibited CTL generation that was dose-
dependent and in a manner similar to that of activated
rHuTGF-01 (Fig. 2). The concentration necessary to inhibit
to 50% (ID5o) the maximal CTL response was 0.63, 0.73
and 0.83 ng/ml acid-activated, latent/acid-activated, and la-
tent rHuTGF-gi, respectively, for the experiment shown
(Fig. 2). These data suggest that latent TGF-0 is effectively
converted to its active form in a manner quantitatively similar
to activation by acid pH. Although the latent preparation
contained ti5% active fraction (as determined by radio-
receptor assay), the [ID5o] for latent, latent/activated, and ac-
tivated rHuTGF-S, suggest that the inhibitory activity is not
the result of pre-existing activated TGF-0but rather the con-
version of latent rHuTGF-01 to active polypeptide.
Tumor Growth and TGRO Production In Viva Tumor
growth was observed in nu/nu mice injected subcutaneously
with 1 x 107 CHO/TGF-S, cells (Table 2). Over the 30-d
examination period, the tumors grew progressively but were
nonlethal. Tumor formation was observed in some animals
as early as the first day after cell inoculation, with all animals
demonstrating measurable tumors by day 5 after the study
start. Elevated TGF-0, levels were observed in the CHO/
TGF-Q1 bearing nu/nu mice compared with baseline levels
of untreated controls (Table 2). Serum levels of activatable
TGF-0increased as the study progressed, and tumors increased
in size. In the two animals, which regressed the CHO tumor
(one on day 14 and the other on day 30) the serum TGF-R
levels were significantly lower in comparison with those ob-
tained for the tumor bearing mice (data not shown). These
results suggest that the CHO/TGF-/3, cells linescontinue to
synthesize rHuTGF-/31 in vivo which circulates in a latent
but potentially activatable form.
E~fect ofrHuTGRO, on Murine Lymphoid Functions.
￿
Acid-
activated human platelet--derived TGF-I01 has been shown to
inhibit NK activity in vitro (26). However, the effects o£ both
latent and acid-activated TGF-O, on NK activity in vivo have
not been reported. As shown in Fig. 3 A, the i.p. injection
of 1 gg acid-activated rHuTGF-01 suppressed NK activity
even after a single administration. Maximum inhibition was
observed when rHuTGF-(31 was administered daily. Less sup-
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BALB/c nu/numice were used; injections, tumormeasurements, anddeterminations of serum TGF-0levels were performedas indicatedin Materials
and Methods
Represents serum levels of activated TGF-0 ± SEMobtained after acid-activation for tumor-bearing animals. Allnonacid-activated serumcontains
less than detectable levels of TGF-fl (detection limit 20 pg/ml).
t Average size ± SEM includes only tumor-bearing animals.
Table 2. Serum TGF-,B Levels and Growth of CHO/TGF-,B, Cells in nu/nu Mice
Average serum levels Tumor Average tumor
Day of study TGF-0 (pg/ml)" incidence size (mm)t
CHO/TGF-0, clone 5 23,256 ± 11,574 3/3 3.25 ± 0.48
61-1/70C12A 10 76,063 ± 50,216 4/4 3.63 ± 0.31
14 105,775 ± 62,404 3/4 5.67 ± 1.42
30 186,368 ± 59,785 3/4 9.33 ± 1.92
Untreated control mice 30 25,374 ± 2,710 0/4 0U
aD
(L
25:1 50:1 100:1 25:1 50:1 100:1 25:1
Effector : Target Cell Ratio
pression was obtained when 0.1 Ag rHufGF-)3 was admin-
istered (data not shown). Administration of 2 pg of activated
rHdrGF-P1 daily by either the intraperitoneal, intravenous,
or subcutaneous route reduced NK activity to a similar de-
gree (Fig. 3 B). The i.p. administration of rHuTGF-01
proved consistently the most effective in suppressing NK ac-
tivity. As our previous data demonstrated that predominantly
latent rHuTGF-01 was produced in vivo by CHO/TGF-,81
cellswe questionedwhether mice bearing these CHO-TGF-
(31 tumors exhibited changes in NK activity. The results
demonstrated a significant reduction in NK activity in the
tumor-bearing mice (Fig. 3 C). NK activity for nulnu mice
bearing CHO dhfr+ cell tumors was similar to that of un-
treated control animals (data not shown). The spleen cells
from mice administered 1 jig rHuTGF-01 intraperitoneally
which showed reduced NK activity also demonstrated a sup-
pressed responsiveness to Con A in comparison with untreated
control animals (data not shown). However, it is interesting
that in certain studies, mice treated with rHuTGF-01 demon-
strated reduced NK levels without the concomitant suppres-
sion ofCon A responses (data not shown). The findings sup-
port that latent TGF-(3 activated in vivo can suppress NK
activity and the ability to respond to mitogenic stimuli.
Treatment with rHuTGF-f1 Prolongs Organ Graft Survival in
Heart TransplantRecipient Mice. Additional studies were per-
formed to determine the efficacy of activated rHuTGF-01 as
an immunosuppressant in organ transplantation. C3H/km
recipients of BALB/c heart allografts were treated intra-
peritoneally with 1 ug or 5 jug activated rHuTGF-fl, on days
1-13 or 4-13 aftertransplant. The drug delivery schedule in-
cluded the days before and after allograft vascularization, day
4, and the period ofallograft rejection, days 10-14. Allograft
survival time was defined as the first day on which graft con-
traction, i.e., rejection, ceased. The data in Table 3 indicate
that percent heart graft survival in rHuTGF-fl1-treated groups
was significantly prolonged using both rHuTGF-01 doses
compared with the saline treated control group. No sig-
nificant difference in mean graft survival time was observed
between treatment groups administered activated rHuTGF-01
on either day 1 or day 4 after transplantation (Table 3).
rHuTGF-/31 was an effective immunosuppressant, with graft
survival time of 16.0 d compared with 10.6 d for control
using the 5 p,g/2.5 lAg combination dose. Cyclosporin A re-
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Figure 3.
￿
TGF-,3,-mediated inhibition off murine NK
activity. NK activities are shown for: (A) C3H/Hej mice
injected intraperitoneally with 1Wg dosage ofadd-activated
rHuTGF-01 givendaily (days 1-7) (0), on alternative days
(days 1,3,5,7) (A), day 1 only (/), or control (O): (B)
C3H/Hej mice given 2 fag once daily (days 1-7) dosage
of rHuTGF-Ot as a function of route of administration,
or (C) untreated control (O), or experimental nulnu mice
injected subcutaneously 30 d before with CHO/TGF-01
cells ("). Each data point represents the mean NK ac-
tivity ± SEM determined from five animals.
quired higher doses of 3-6 mg/kg in this model to achieve
similar graft survival (data not shown). In addition, activated
rHuTGF-/31 also suppressed the T cell-mediated increased
lymph node enlargement occurring in host-versus-graft
popliteal lymph node assay (data not shown).
Discussion
We have examined the immunoregulatory effects of
TGF-13 using CHO lines that synthesize and secrete latent
rHuTGF-(31. Latent TGF-/3 was chosen as substrate to define
the conditions underwhich immune cells process latent TGF-f
to a functional polypeptide. The latency of rHuTGF-01 was
determined by inactivity in biological growth inhibition and
radioreceptor assays. While it is generally true that most cells
synthesize latent TGF-0(3), some cell lines such as the human
breast cancer cell lines MCF-7 and T-47D, and human glio-
blastoma cells have been reported to secrete TGF-a that is
biologically active without activation by acid, pH, or urea
(39-41) . The different mechanisms regulating the decision
whether to release TGF-a as active or latent product is cur-
rently unclear. Since only active TGF-/l can bind to cellular
receptors (10), elucidation of those cells that can either acti-
Table 3.
￿
Effect of rHuTGF,B, on an Heterotopic Murine
Heart Graft Survival
2.5 1tg
￿
7, 9, 11, 13
BALB/c neonatal hearts were transplanted into C3H/km mice as described
in Materials and Methods. 1 or 4d after surgery, mice were injected in-
traperitoneally with indicated amounts of rHuTGF-01 or saline control.
' Results are reported as mean ± the 95% confidence limit.
rHuTGF-01
treatment n
Mean graft
Schedule survival time`
p Value vs.
control
d d
None 105 1-13 10.6 ± 0.2 -
1 jug 10 1-13 12.9 ± 1 .5 <0.00006
1 tUg 4 4-13 12.5 ± 1 .6 0.002
5 jug/ 3 1-6/ 16.0 ± 4.3 <0.0003vate TGF-0 directly, or are in proximity to those cells that
can, is important for the understanding of autocrine or-para-
crine regulation by TGF-(3. However, at least for some cells,
the masking of active TGF-0 by association with "latency-
associatedpeptide" (LAP) appears an important means to pro-
tect themselves from the potent regulatory effects of TGF-0
they synthesize (1, 8, 20-22, 42) .
In keeping with the protective role of LAP, we found that
CHO/TGF-R1 cells injected into nu/nu mice secrete
rHuTGF-N1 into the animal's circulation as latent protein.
Since activated TGF-R1 was not found systemically at detect-
able levels in CHO/TGF-R1 recipient nu/nu mice, but is re-
quired to decrease NK activity, the results suggest that
TGF-01 activation is a localized event in vivo, safeguarding
the release of large amounts of this growth regulator. The
localized activation of latent TGF-0 may provide a means for
cells to regulate TGF-0 activity only in specific tissues.
In addition to being sensitive to the inhibitory effects of
TGF-R1, most lymphoid cells produce latent TGF-0. The
presumed conversion of latent or endogenous rHuTGF-01 to
an active form that can inhibit immune functions was shown
to occur both in vitro and in vivo. Kehrl et al. have recently
reported that polyclonal antibodies to active TGF-0 can en-
hance B-cell proliferation and Ig synthesis (22). In addition,
Lucas and co-workers have shown that mAbs to active TGF-0
can enhance the proliferation ofPBMC to IIr2 and PHA/PMA
as well as the generation oflymphokine-activated killer cells.
These findings suggest that endogenously produced latent
TGF-0 canbe activated by normal physiological mechanisms
which can then downregulate in an autocrine fashion these
immune functions (43). The studies presented here further
demonstrate that endogenous latent TGF-0 can be activated
and suppress both CTL generation in vitro and NK activity
in vivo.
A key towards understanding the target specificity ofTGF-0
action is elucidation of the processes by which latent TGF-0
becomes biologically active. Recent studies have suggested
that activated macrophages have the potential to both secrete
and activate latent TGF-0, although the mechanisms involved
in this conversion are not known. Acidic conditions can con-
vert latent TGF-0 to active (11), suggesting that acidic cel-
lular environments may provide a physiologic milieu in which
activation may occur (44, 45). From microelectrode studies
it has been shown that macrophages, as well as osteoclasts,
contain such acidic microenvironrnents (46) that may be
sufficiently low to activate TGF-f3. Moreover, the observa-
tion that activated macrophages express sialidase activity (47),
coupled with the finding that removal of sialic-acid-containing
carbohydrate structures in the TGF-0 precursor remnant can
activate TGF-0 (14), further substantiates the possible role
of the macrophage as an activator of latent TGF-/3. We have
found that LPS-stimulated human peripheral blood-derived
adherent macrophages did not significantly activate ex-
ogenously added purified latent TGF-,B1 (data not shown).
This result does not preclude the possibility that antigen-
presenting macrophages can activate latent TGF-(3, but may
indicate the need for cognate help by othercell types during
activation. In support of this hypothesis, Antonelli-Orlidge
et al. report that the conditioned media of endothelial cells
and pericytes each contained latent TGF-(3, but only during
their co-culture can activated TGF-0 be produced (48). At
the current time we have no information to support or ex-
clude the possibility that CHO or CHO-TGF-01 cells them-
selves can activate latent TGF-/3. Our results showing that
activation of latent TGF-0 occurs during the generation of
immune cytolytic cells may indicate that de novo induction
of lymphoid maturation proteins or cell surface differentia-
tion markers are pre-requisites for TGF-0 activation.
Once activated, TGF-R1 displays potent immunosuppres-
sion in vivo of NK cytolytic activity, the ability of spleno-
cytes to respond to mitogenic stimuli, and CTL generation
in vitro, which are shown in this report and previously (26-28).
As suggested by Rook et al., TGF-0may affect the continuous
recruitment and activationof "pre-NK" cells by blunting their
ability to respond to IFN-a, an important growth factor for
NK activation and function (26). The blunting of IFN-a
responsiveness may reflect downregulation of IFN-ci receptor
numbers expressed on NK cells by TGF-0. In addition, TGF-0
may affect the differentiation oflymphoid cells as shown for
Ig-secreting B cells (21, 22), CTLs (27), and LAK cells (30),
possibly by lowering lymphocyte cell receptors for 11,2 (20).
Alternatively, TGF-(3 may inhibit the generation of CTLs,
and also LAK cells, by dampening TNF-ci production (25),
an important modulator ofboth CTL and LAK cell develop-
ment (27, 30). Interestingly, TGF-0does not effect the ability
of either lymphoid cells (27) or tumor cells (data presented
here) to serve as targets for lysis by mature CTLs. This finding
suggests that TGF-N1 might not affect MHC class I expres-
sion on CHO cells, in contrast to its ability to modulate class
II HLADR surface antigen expression on human cells
(34, 35) .
Within the framework of the complex immune cell net-
work, TGF-0 is also shown to downregulate both NK ac-
tivity and primary CTL responses in vivo (49). Tumor cells
that produce TGF-0 may therefore potentially reduce the
numbers or generation of circulating rytolytic CTL and NK
cells and thus promote escape of the tumor from immune
surveillance. Clinically, patients with glioblastomas, which
secrete TGF-/32 (50), demonstrate a generalized immune sup-
pression; manifested especially by an inability of normal T
cells to respond to mitogens (51). Moreover, TGF-J3-producing
tumors can grow progressively in transiently immunosup-
pressed mice while retaining expression for class I MHC (49).
Thus, TGF-0 by inhibition of host immune responses may
provide a mechanism to suppress allograft rejection and may
possibly accelerate processes of carcinogenesis.
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